The field of genetic therapies needs robust investments, transparency and reliable regulatory frameworks to overcome recent challenges and continue to translate new technologies into patients’ benefit.
More than 50 gene therapies have now received approval globally with many more products nearing registration. Notably, the first personalized gene-editing therapy was developed in record time to sav...
The strongest version of this narrative highlights the duality of progress and peril in genetic therapies. On one hand, the field has achieved remarkable milestones—personalized gene editing saving a newborn’s life, prime editing reaching clinical trials in record time, and over 50 therapies approved globally. These successes underscore the transformative potential of genetic medicine. On the other hand, the decline in active development programs, safety setbacks, and regulatory uncertainties pa...